The FDA's safety claim for Zimmer's injection indicates the product is safe to use in repeat treatments for knee osteoarthritis patients.
Here are four notes:
1. Gel-One Cross-linked Hyaluronate is single-injection viscosupplement for the knee joint.
2. The injection is intended for knee osteoarthritis patients who have not responded adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs or simple analgesics.
3. Zimmer's product is the first low-volume viscosupplement available in a single-injection formulation for treating knee osteoarthritis.
4. To complete the treatment course, Gel-One Cross-linked Hyaluronate requires a single 3mL injection.
More articles on devices:
5 key trends in the North American orthobiologics market
OrthoSera launches BoneAlbumin: 4 things to know
Xtant Medical receives FDA clearance for expanded product indications: 4 takeaways